附件一

IGDRP
International Generic Drug Regulators Pilot

July 23, 2014

First Expression of Interest (EOI) to Participate in an Information Sharing Pilot for the *Evaluation of Generic Drug Applications involving the Decentralised Procedure (DCP) of the European Union*

The *International Generic Drug Regulators Pilot* (IGDRP)[1] was launched in April 2012 in the face of mounting pressures that confront generic drug review programs worldwide and a willingness on the part of regulatory agencies to pursue collaboration and convergence in order to help mitigate these pressures. Broadly speaking, this would be realized through:

- increasing the efficiency of review procedures;
- strengthening the regulatory review process and human resource capacity;
- applying an appropriate level of global regulatory oversight through information exchange and coordination, while reducing unnecessary regulatory burden; and
- promoting the adoption of modern science and risk based approaches on the part of both industry and agencies.

Information sharing mechanisms and work-sharing models offer important means of achieving these objectives. One of the most significant developments in this regard involves the piloting of the European Union's Decentralised Procedure (DCP) as a model for the sharing of information with IGDRP competent authorities external to the EU during the scientific assessment phases of the DCP.

A generic drug applicant wishing to market the same product in the EU through the DCP and in other jurisdictions that form part of IGDRP are invited to participate in this pilot provided that the criteria for eligibility listed below are met. This would include the requirement to file marketing applications in a synchronized manner in at least one of the IGDRP participating jurisdictions. A list of regulatory agencies that have expressed an interest to participate in the first round of the pilot is provided in Appendix 1. Additional agencies may choose to participate in subsequent stages of this pilot.

[1] World Health Organization (WHO) Drug Information Vol. 28 No. 1, 2014 (www.who.int/medicines/publications/druginformation/DI_28-1_Regulatory-Harmonization.pdf?ua=1)

Under the arrangements established for the pilot, the assessment reports generated as part of the DCP would be shared in real time with collaborating IGDRP agencies outside the EU, as illustrated in the schematic in Appendix 2.

Participation in the pilot would offer applicants the potential to obtain market authorization in chosen markets as part of a coordinated process. Experience gained by industry and regulatory agencies would help to refine the process and inform other information and work sharing models currently under consideration by regulatory agencies. The objective of the pilot is to provide for a more efficient and consistent review process while at the same time reducing regulatory burden and facilitating the similar timing of market authorizations across jurisdictions.

The applicant is required to provide consent to share the DCP assessment reports (Preliminary, Draft and Final) with the non-EU agencies proposed in the EOI. In order to further promote the value and impact of the pilot, interested applicants are requested to provide consent for the sharing of DCP assessment reports) with other regulatory agencies that form part of IGDRP or may be of interest from a marketing perspective (see EOI Request form, Appendix 3).

Expressions of Interest related to the pilot should be forwarded to the contact points for candidate agencies selected by the applicant (see Appendix 1) and the CMDh Secretariat (H-CMDhSecretariat@ema.europa.eu) **at least 8 weeks prior to the intended submission** of the application using the EOI form. Applicants should also inform the proposed Reference Member State (RMS) of the EU DCP and the CMDh-Member (http://www.hma.eu/352.html) of this member state about the intention.

Applications to this EOI are requested by 26 September, 2014.

Criteria for Eligibility for the Pilot

In order to qualify for consideration in the pilot, interested applicants must comply with the following criteria:

- Synchronized filing of generic drug applications for the same product in at least one of the IGDRP participating jurisdictions selected for the pilot. Synchronized filing means the applications are submitted at times defined by participating non-EU agencies in relation to the time of filing of the DCP application. The timing will be made available by the IGDRP participating jurisdictions and will be defined in a manner that best aligns the review processes and the flow of information. This may be simultaneous or sequential, depending on the agency.
- Minor differences in products from the product that is intended to be authorised in the EU may be considered acceptable provided these differences are not expected to

impact on the safety, efficacy or quality of the product and ensure a similarity the products/dossiers under assessment (e.g., differences in container closure system formats). Non-EU regulatory agencies identified for collaboration in the pilot will confirm the acceptability of any such differences upon review of information submitted with the EOI, including the completed *Summary of Quality Differences* (see below).

- Complete applications, compliant with respective regulatory requirements, will be filed with the jurisdictions participating in the exercise.
- Original generic drug applications for the following pharmaceutical (dosage) forms:
    - immediate-release, solid oral
    - solutions (e.g., oral, injectable)
- When in-vitro or in-vivo comparative studies against a reference product are warranted, comparative studies should be against the reference product marketed in the jurisdiction of the non-EU regulatory agency participating in the pilot, or against another suitable reference product with the condition that the non-EU agency's requirements for the use of a foreign-sourced reference product are met.
- A completed *Summary of Quality Differences* form is submitted noting the differences, if any, between the products filed with the EU DCP and the non-EU agency (Appendix 4).
- Consent is provided granting permission for the sharing of DCP assessment reports with non-EU agencies involved in the pilot (Appendix 3).
- Practical knowledge on how to apply and run an EU-DCP is deemed as a prerequisite.

A verification assessment will be undertaken by non-EU agencies to determine whether the product being evaluated meets eligibility criteria.

Appendix 1 - List of Regulatory Agencies interested in participating in the first DCP Information Sharing Pilot

Jurisdiction	Regulatory Agency	Contact Information
Australia	Therapeutic Goods Administration (TGA)	TGA.International@tga.gov.au
Canada	Health Canada	TPD-DTP.international@hc-sc.gc.ca
Chinese Taipei	Taiwan Food and Drug Administration (TFDA)	lin.bond@fda.gov.tw
Switzerland	Swissmedic – Swiss Agency for Therapeutic Products	Networking@swissmedic.ch

Appendix 2 – Schematic of how DCP Pilot would operate

The EU has offered to pilot the DCP as a model for the sharing of information with IGDRP regulatory agencies external to the EU during the scientific assessment phases of the DCP. This would involve a parallel review process, with non-EU agencies continuing to conduct separate but synchronized receipt, validation/screening, assessment and market authorization (or refusal) steps, using the outputs from the Step 1 and 2 DCP to inform their scientific assessments



Appendix 3

Expression of Interest (EOI) Request to Participate in the First Information Sharing Pilot for the *Evaluation of Generic Drug Applications involving the Decentralised Procedure of the European Union*

Product Information			
Product Name (should be same as on product label):			
Active Pharmaceutical Ingredient:			
Pharmaceutical Form	Route	Strength	Conditions of Use

Applicant Information		
Name (Full legal name):		
Address:		
Contact Person:		
Tel:	Fax:	Email:

Application/submission filing information
Intended filing date in EU Reference Member State:
Reference Member State (RMS):
DCP-Number (if already known):
Concerned Member States (CMS):
Non-EU agencies proposed for this pilot: ☐ Australia (Therapeutic Goods Administration (TGA)) ☐ Canada (Health Canada) ☐ Chinese Taipei (Taiwan Food and Drug Administration (TFDA)) ☐ Switzerland (Swissmedic, Swiss Agency for Therapeutic Products)

Confirmation of Meeting Eligibility Criteria for Pilot
This marketing application complies with all of the eligibility criteria listed in the Expression of Interest Notice including the following: Original generic drug application for the following pharmaceutical (dosage) forms: ☐ immediate-release, solid oral ☐ solutions (e.g., oral, injectable) ☐ When in-vitro or in-vivo comparative studies against a reference product are warranted, comparative studies comply with the requirements of the non-EU agencies proposed in this EOI request, as substantiated by evidence appended to the completed EOI Request.

☐ A completed Summary of Quality Differences form is included as part of this EOI Request.

Consent to share regulatory information

The undersigned hereby acknowledges and gives consent to the sharing of DCP assessment reports with the IGDRP agencies proposed in this EOI Request.

In addition, the undersigned hereby acknowledges and gives consent to the sharing of the same information :

☐ with all IGDRP agencies*, or
☐ with the following agencies:_____

Name of Authorized Signing Official: _____

Title, Company: _____

Signature**: _____

Date: _____

* Agencies from the following jurisdictions form part of IGDRP: Australia, Brazil, Canada, China, Chinese Taipei, the European Union, the Republic of Korea, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, Switzerland and the United States as well as the World Health Organization.

**Signatures (including digital/electronic versions, where permitted) must comply with the legal requirements of the jurisdiction(s) in which the EOI is being submitted.

Appendix 4 – Summary of Quality Differences

This form must be completed and submitted to each Non-EU agency proposed in the EOI Request

Summary of Quality Differences

Modules and numbering reflect the ICH Common Technical Document.

Modules where there are no differences between the products filed with the EU DCP and the non-EU agency should be reported as "No differences". Where minor differences exist for a listed module, **a brief summary** of the differences should be provided.

Module	Information in application to be filed with the EU DCP	Information in application to be filed with the non-EU agency	Brief discussion of noted differences
3.2.S Drug Substance			
3.2.S.1 General Information			
3.2.S.2 Manufacture			
3.2.S.3 Characterisation			
3.2.S.4 Control of the Drug Substance			
3.2.S.5 Reference Standard or Materials			
3.2.S.6 Container Closure System			
3.2.S.7 Stability			
3.2.P Drug Product			
3.2.P.1 Description and Composition of the Drug Product			
3.2.P.2 Pharmaceutical Development			
3.2.P.3 Manufacture			
3.2.P.4 Control of Excipients			
3.2.P.5 Control of Drug Product			

Summary of Quality Differences

Modules and numbering reflect the ICH Common Technical Document.

Modules where there are no differences between the products filed with the EU DCP and the non-EU agency should be reported as "No differences". Where minor differences exist for a listed module, **a brief summary** of the differences should be provided.

Module	Information in application to be filed with the EU DCP	Information in application to be filed with the non-EU agency	Brief discussion of noted differences
3.2.P.6 Reference Standard or Materials			
3.2.P.7 Container Closure System			
3.2.P.8 Stability			

參與歐盟分散式審查程序之第一梯次學名藥查驗登記資訊共享先導計畫計畫書

為減緩日益龐大的全球學名藥查驗登記審查壓力以及響應審查機構之間合作及協和化之呼聲，IGDRP(the International Generic Drug Regulators Pilot)於 2012 年 4 月成立。廣泛來說，實現目標的方式有

- 增加審查效率
- 強化審查程序以及人力運用
- 藉由資訊交換及協同合作，提供適當程度的全球審查機制，以期降低不必要的審查負擔，以及
- 鼓勵業界及政府採用當代科學以及危機控管的處理方式

資訊共享(Information Sharing)的機制以及業務分工(Work-Sharing)的模式是達成這些目標的重要的方法。目前最主要的進程為試辦「以歐盟分散式審查程序(Decentralized Procedure; DCP)之模式，於 DCP 的技術審查階段，對非歐盟成員之 IGDRP 會員進行資訊共享」。

誠摯邀請符合下列條件又計畫在歐盟藉由 DCP 上市以及在部分 IGDRP 會員管轄區上市同一個學名藥的申請者參與此項先導計畫。此計畫包含必須同步提交上市申請於至少一個 IGDRP 參與之管轄區。試辦計畫第一梯次參與審查機構詳見附件一，其他審查機構也許會選擇參與其他梯次的試辦。

依據先導計畫，DCP 的審查報告(the Assessment Report)會及時分享給不屬於歐盟的 IGDRP 共同審查機構，流程圖詳見附件二。

參與先導計畫可以藉由協同過程，提供申請者獲得特定市場之上市許可的機會。由業界以及審查機構獲得的經驗可以幫助改善協同程序以及幫助其他由審查機構考慮的資訊共享以及業務分工模式。計畫的目標為提供一個更有效以及一致的審查過程，並同時減輕審查負擔以及協助產品在不同管轄區同時獲得上市許可。

申請者須同意將 DCP 審查報告(初稿、草稿、完稿)給本次申請書(Expression of Interest; EOI)中參與之非歐盟機構使用。為了更進一步提升本計畫的價值及影響力，有興趣的申請者亦須同意將 DCP 審查報告給予其他 IGDRP 審查機構使用或是選擇部分對上市有興趣的審查機構使用(詳見附件三，EOI 申請書)。

本次先導計畫的參與意願須於擬使用 EOI 表格送件前的 **8 個星期**送達申請者選擇的候選審查機構聯絡點(詳見附件一)以及 CMDh 秘書處

(H-CMDhSecretariat@ema.europa.eu)。申請者亦須知會所提議的 DCP 的主審國(Reference Member State; RMS)，以及該國之 CMDh-Member(http://www.hma.eu/352.html)有關參與的意願。

申請須於 2014 年 9 月 26 日前提出。

試辦計畫參加條件

為符合先導計畫的考量，有興趣的申請者須要符合以下條件：

- 同一產品最少選擇一參與本先導計畫之 IGDRP 共同審查機關「同時送件」。「同時送件」指的是前述之機關對於歐盟 DCP 送件時間與該機關收件的時間而定。送件時間將由參與的 IGDRP 審查機構公布，而且會盡可能促成審查最佳同步化以及審查資訊交流。依照審查機構的不同，送件時間有可能是同時或有先後順序。

- 可以接受申請的產品與擬於歐洲上市的產品有些微差異，只要這些差異與產品之安全性，療效以及品質無影響，並且保證審查的產品/檔案相似(例如：容器加蓋系統的形式不同)。參與先導計畫的非歐盟共同審查機構會審查與 EOI 一併寄來的資料[包含完整填好的品質對照表(Summary of Quality Differences) (詳見底下)]以確認不同處的可接受性。

- 依據各參與審查機構的要求，申請者須檢送完整資料供核。

- 須為該廠全球首次申請的學名藥查驗登記且劑型為：

  - 速放、口服固體製劑，或

  - 液劑(如：口服、注射)

- 當需要執行溶離曲線比對試驗或是生體相等性試驗時，比對試驗應選擇於參與此次先導計畫之非歐盟地區上市的對照品，或符合非歐盟審查機構對外國對照品的使用要求。

- 假如在非歐盟地區送件的產品與擬藉由歐盟 DCP 上市的產品有差異，須完整填寫品質對照表並註明不同處。

- 允許共享 DCP 審查報告給此次先導計畫的非歐盟審查機構(附件 3)。

- 申請者應對歐盟的 DCP 查驗登記程序須有認知。

非歐盟審查機構將負責決定申請審查的產品是否符合試辦計畫的資格。

附件一　參與第一梯次試辦計畫的審查機構名單

附件二　DCP 試辦計畫程序流程圖：歐盟提出以 DCP 模式，於 DCP 的技術審查階

段，對 IGDRP 非歐盟審查機構試辦資訊共享。這包含一個平行的審查過程，由非歐盟審查機構持續進行分開但同步的收件、確認/篩選、審查、核發(或拒絕核發)上市許可的步驟，歐盟則將 DCP 步驟一及步驟二的審查結果知會非歐盟審查機構。

附件三　參與歐盟分散式審查程序之第一梯次學名藥查驗登記資訊共享先導計畫申請書。

附件四　品質對照表：須完整填寫並寄給申請書勾選之每一個非歐盟審查機構。